108 related articles for article (PubMed ID: 10705778)
21. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis.
Marras TK; Nopmaneejumruslers C; Chan CK
Am J Med; 2004 Mar; 116(6):385-93. PubMed ID: 15006587
[TBL] [Abstract][Full Text] [Related]
23. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
[TBL] [Abstract][Full Text] [Related]
24. Effect of a simple educational intervention on the hospital management of community-acquired pneumonia.
Serisier DJ; Bowler SD
Respirology; 2007 May; 12(3):389-93. PubMed ID: 17539843
[TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of linezolid in children.
Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
[TBL] [Abstract][Full Text] [Related]
26. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Tellier G; Chang JR; Asche CV; Lavin B; Stewart J; Sullivan SD
Curr Med Res Opin; 2004 May; 20(5):739-47. PubMed ID: 15140341
[TBL] [Abstract][Full Text] [Related]
27. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
28. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
Davis SL; Delgado G; McKinnon PS
Clin Infect Dis; 2005 Jul; 41 Suppl 2():S136-43. PubMed ID: 15942880
[TBL] [Abstract][Full Text] [Related]
29. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
30. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia.
Jasti H; Mortensen EM; Obrosky DS; Kapoor WN; Fine MJ
Clin Infect Dis; 2008 Feb; 46(4):550-6. PubMed ID: 18194099
[TBL] [Abstract][Full Text] [Related]
31. Duration and route of antibiotic therapy in community-acquired pneumonia: switch and step-down therapy.
Cassiere HA; Fein AM
Semin Respir Infect; 1998 Mar; 13(1):36-42. PubMed ID: 9543474
[TBL] [Abstract][Full Text] [Related]
32. [Acute community acquired pneumonia: 96 cases in Madagascar].
Rakotoson JL; Rakotomizao JR; Andrianarisoa AC
Med Trop (Mars); 2010 Feb; 70(1):62-4. PubMed ID: 20337118
[TBL] [Abstract][Full Text] [Related]
33. [Rovamycin (spiramycin)--a macrolide antibiotic for intravenous administration: a trial in the treatment of pneumonia].
Strachunskiĭ LS; Sudilovskaia NN; Melikhov OG
Ter Arkh; 1995; 67(3):7-11. PubMed ID: 7770811
[TBL] [Abstract][Full Text] [Related]
34. [Can macrolide treatment delay the diagnosis of tuberculosis?].
Gómez Cubillos C; Carrión Valero F; Pascual Izuel JM
An Med Interna; 1999 Jul; 16(7):385-6. PubMed ID: 10481348
[No Abstract] [Full Text] [Related]
35. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults.
Sopena N; Martínez-Vázquez C; Rodríguez-Suárez JR; Segura F; Valencia A; Sabrià M
J Chemother; 2004 Feb; 16(1):102-3. PubMed ID: 15078008
[No Abstract] [Full Text] [Related]
36. Intravenous clarithromycin.
Winter J
Br J Hosp Med; 1994 Mar 16-Apr 5; 51(6):295-6. PubMed ID: 8032567
[TBL] [Abstract][Full Text] [Related]
37. Community-acquired pneumonia. Cost-effective antimicrobial therapy.
Cunha BA
Postgrad Med; 1996 Jan; 99(1):109-10, 113-4, 117-9, passim. PubMed ID: 8539197
[TBL] [Abstract][Full Text] [Related]
38. Community-acquired pneumonia: diagnosis and therapy of older adults.
Brown RB
Geriatrics; 1993 Feb; 48(2):43-50. PubMed ID: 8432435
[TBL] [Abstract][Full Text] [Related]
39. [Clinical efficacy of clarithromycin delayed release dosage form in the treatment of community-acquired pneumonia].
Iutanova NS
Antibiot Khimioter; 2004; 49(3):17-21. PubMed ID: 15344392
[TBL] [Abstract][Full Text] [Related]
40. Clarithromycin-induced hypomania in a child - a case report.
Baranowski WJ
Acta Psychiatr Scand; 2010 Sep; 122(3):267-8. PubMed ID: 20491717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
